KOSPI Hits Record High as AI Chip Demand Boosts Samsung and SK Hynix 
Trump Administration Seeks Court Pause to Reinstate 10% Global Tariffs 
Gold Prices Slip as Strong Dollar and Rising Oil Weigh on Market Sentiment 
Trump Rejects Iran Proposal as Strait of Hormuz Crisis Pushes Oil Prices Higher 
Goldman Sachs Delays Fed Rate Cut Forecast to 2026 Amid Rising Inflation Concerns 
Indian Stock Market Drops as Iran Conflict Fuels Oil Price and Inflation Fears 
Trump Says Iran Ceasefire ‘On Life Support’ as Oil Prices Surge Above $104 
Asian Currencies Slide as Iran Tensions Boost Dollar and Oil Prices 
South Korea Central Bank Signals Inflation Concerns as Oil Prices Surge 
Trump to Visit China for Key U.S.-China Summit With Xi Jinping 
Oil Prices Rise as Dollar Gains Ahead of Key U.S. Inflation Data 
US Stock Futures Hold Steady Ahead of CPI Data and Iran Conflict Concerns 
Rubio Discusses Iran Crisis and Strait of Hormuz Disruptions With UK and Australia 
Dollar Rises as Strait of Hormuz Crisis Pushes Oil Prices Higher 
US, Japan Reaffirm Strong Currency Coordination Amid Yen Volatility 
China Inflation Jumps as Iran Conflict Drives Energy Costs Higher 
Dollar Gains on Safe-Haven Demand as Iran Tensions and Inflation Data Loom 
Swiss pharmaceutical leader Roche confirmed it has no plans for layoffs, emphasizing a healthy business outlook. CEO Thomas Schinecker highlighted steady research funding and workforce stability despite global economic challenges in Europe and China, as well as setbacks in cancer drug development.
Roche Maintains Workforce Stability Amid Market Challenges
Roche, a Swiss pharmaceutical corporation, does not intend to reduce its workforce, and the company's business is doing well. According to a statement made by CEO Thomas Schinecker, which was published in a Swiss publication on Sunday, Investing.com shares.
The stock price of Roche has dropped significantly below the highs it reached in April 2022, and the CEO was questioned about the company's plans for personnel in light of recent setbacks in the company's efforts to produce pharmaceuticals to cure a variety of illnesses, including cancer.
Schinecker responded to a question about whether or not the company was preparing to lay off employees by saying, "The number of workers is constant to slightly increasing," during an interview with the NZZ am Sonntag.
Research and Development Budgets Remain Steady
"I can say with certainty that we have a very healthy business. And we don't have a growth problem either," he remarked, pointing out that Roche's funding for research and development was consistent and not expanding. He also included this information in his statement.
When Schinecker was asked when Roche's intended anti-obesity medicine would be available for purchase, he responded that it may be as early as 2029 or perhaps earlier.
European Economic Struggles Create Headwinds for Recovery
While discussing the forecast for the coming year in a broader sense, particularly in light of the recent difficulties that the German economy has been experiencing, the CEO of Roche stated that Europe still faced problems.
"There's some economic growth in the United States, but things are more difficult in China at the moment," he explained to reporters. "And in Europe it will take some time before we get out of this."
